Moleculin Biotech's total assets for Q3 2024 were $23.39M, a decrease of -8.53% from the previous quarter. MBRX total liabilities were $15.91M for the fiscal quarter, a 102.22% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.